Elsevier

Ophthalmology

Volume 100, Issue 9, September 1993, Pages 1297-1304
Ophthalmology

Effects of PhXA41, A New Prostaglandin F2α Analog, on Aqueous Humor Dynamics in Human Eyes

https://doi.org/10.1016/S0161-6420(93)31484-3Get rights and content

Purpose: PhXA41, a new phenyl-substituted analog of a prostaglandin F2α (PGF2α) prodrug (13,14-dihydro-17-phenyl-18,19,20-trinor-prostagland in F2α-1-isopropyl ester), is an effective ocular hypotensive agent in patients with glaucoma. To understand its mechanism of action, various components of aqueous humor dynamics were examined after topical application to human eyes.

Methods: In a randomized, double-masked, placebo-controlled study, PhXA41 (0.006%) was given topically twice daily for 1 week to one eye each of 22 volunteers with normotension or ocular hypertension. The other eye was similarly treated with vehicle. Intraocular pressure (IOP) was measured by pneumatonometry and tonographic outflow facility by pneumatonography. Aqueous flow and outflow facility were determined either directly or indirectly by a fluorophotometric technique, and uveoscleral outflow was calculated secondarily. Comparison of values obtained in treated versus contralateral control eyes and on baseline versus day 8 of treatment were made.

Results: Compared with baseline measurements, PhXA41 significantly (P < 0.001) reduced IOP by 5.5 ± 0.6 mmHg (mean ± standard error of the mean) as measured 3 hours after the last dose on the eighth day of treatment. Aqueous flow, tonographic outflow facility, and fluorophotometric outflow facility were not changed by PhXA41. However, uveoscleral outflow was significantly greater in the PhXA41-treated eyes (0.87 + 0.22 µl/minute) compared with either the contralateral vehicle-treated eyes (0.14 ± 0.30; P < 0.02) or baseline measurements (0.39 ± 0.20 µl/minute; P < 0.05).

Conclusions: PhXA41 decreases IOP in humans by increasing uveoscleral outflow without significantly affecting other parameters of aqueous humor dynamics.

References (48)

  • E Lütjen-Drecoll et al.

    Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2α

    Exp Eye Res

    (1988)
  • C Kupfer

    Clinical significance of pseudofacility. Stanford R. Gifford Memorial Lecture

    Am J Ophthalmol

    (1973)
  • A Bill et al.

    Uveoscleral drainage of aqueous humour in human eyes

    Exp Eye Res

    (1971)
  • P-Y Lee et al.

    Additivity of prostaglandin F2α-l -isopropyl ester to timolol in glaucoma patients

    Ophthalmology

    (1991)
  • BT Gabelt et al.

    Prostaglandin F2α increases uveoscleral outflow in the cynomolgus monkey

    Exp Eye Res

    (1989)
  • SFE Nilsson et al.

    Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey

    Exp Eye Res

    (1989)
  • BT Gabelt et al.

    The effect of prostaglandin F2α on trabecular outflow facility in cynomolgus monkeys

    Exp Eye Res

    (1990)
  • LZ Bito et al.

    The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals

  • CB Camras et al.

    Reduction of intraocular pressure by exogenous and endogenous prostaglandins in monkeys and humans

  • A Alm et al.

    Effects of topically applied PGF2α and its isopropylester on normal and glaucomatous human eyes

  • P-Y Lee et al.

    Effect of prostaglandin F2α on aqueous humor dynamics of rabbit, cat, and monkey

    Invest Ophthalmol Vis Sci

    (1984)
  • J Villumsen et al.

    Prostaglandin F2α- isopropylester eye drops: effects in normal human eyes

    Br J Ophthalmol

    (1989)
  • J Villumsen et al.

    PhXA34-a prostaglandin F2α analog. Effect on intraocular pressure in patients with ocular hypertension

    Br J Ophthalmol

    (1992)
  • A Alm et al.

    PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

    Arch Ophthalmol

    (1991)

    • Cited by (0)

    Presented in part at the Prostaglandin and Related Compounds meeting, Montreal, July 1992, and at the American Academy of Ophthalmology Annual Meeting, Dallas, November 1992.

    Supported in part by grant EY07836 and EY07865 from the National Eye Institute, Bethesda, Maryland, and a contribution from Kabi Pharmacia Ophthalmics, Uppsala, Sweden.

    *

    Drs. Camras and Yablonski are consultants for Kabi Pharmacia Ophthalmics, Uppsala, Sweden, and Allergan Pharmaceuticals, Irvine, California, respectively.

    View full text
    Copyright © 1993 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved.